Re­gen­eron halts place­bo en­roll­ment in Covid-19 cock­tail tri­al af­ter IDMC finds 'clear' ef­fi­ca­cy — but there are no da­ta yet

De­spite hav­ing al­ready re­ceived an emer­gency use au­tho­riza­tion for its Covid-19 an­ti­body in non-hos­pi­tal­ized pa­tients last No­vem­ber, Re­gen­eron con­tin­ued to con­duct tri­als to eval­u­ate the cock­tail’s ef­fec­tive­ness. Now, the big biotech has re­ceived some good news from their IDMC.

On the IDMC’s rec­om­men­da­tion, Re­gen­eron will be shut­ting down en­roll­ment in the place­bo group of a Phase III out­pa­tient tri­al for their REGN-COV pro­gram — a mix of casiriv­imab with imde­vimab — af­ter in­ves­ti­ga­tors found “clear clin­i­cal ef­fi­ca­cy” in both dos­es com­pared to the con­trol, the com­pa­ny an­nounced Thurs­day. CSO George Yan­copou­los al­so said in a state­ment that the cock­tail can neu­tral­ize emerg­ing strains of the nov­el coro­n­avirus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER